Tandem Diabetes Care stock gains 2.36 percent before Q3 results
Tandem Diabetes Care stock rose 2.36 percent to USD 16.89 on Nasdaq ahead of its third-quarter 2026 earnings release scheduled for November 5. The company's Q2 revenue increased by 5.8 percent year-over-year to USD 254.56 million, and its GAAP net loss narrowed significantly. Analysts maintain a "Hold" consensus with an average target price well above the current market price, making the upcoming Q3 results a critical test for the company's valuation.
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $26
RBC Capital has reiterated its Buy rating for Tandem Diabetes Care (TNDM.US), maintaining a target price of $26. This indicates the firm's continued positive outlook on the company's stock performance.
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $20
Citi has reiterated its Hold rating on Tandem Diabetes Care (TNDM.US) but has lowered its target price for the stock from $23 to $20. This adjustment reflects an updated outlook on the company's valuation.
TNDM Maintained by Citigroup -- Price Target Lowered to $20
Citigroup has maintained a Neutral rating on Tandem Diabetes Care (TNDM) but lowered its price target from $24.00 to $20.00, reflecting a cautious outlook despite the stock appearing 32.8% undervalued by GF Value™. The company, specializing in insulin delivery systems, faces challenges with unprofitability and financial strength, though it shows strengths in growth and momentum with a GF Score™ of 69/100. Gurus show mixed activity, while insiders have reported no recent buying or selling.
Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks
This article analyzes Q2 earnings for Tandem Diabetes (NASDAQ:TNDM) and other healthcare technology stocks. Tandem Diabetes met analyst expectations for revenue and EPS, but its stock declined. Evolent Health (NYSE:EVH) had the strongest quarter with significant beats, while Astrana Health (NASDAQ:ASTH) and Omnicell (NASDAQ:OMCL) had mixed results with Omnicell showing the weakest guidance update. The report highlights sector trends, including demand for digital health solutions and regulatory challenges.
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
Tandem Diabetes Care (TNDM) stock rose 7.2% following the international launch of its Mobi insulin pump system in 12 countries, integrating with Dexcom G7 CGM and Control-IQ+ technology. This expansion supports Tandem's goal of broader international adoption and reinforces its focus on sensor interoperability and recurring supply revenue. Analysts project significant revenue and earnings growth for Tandem Diabetes Care, with a fair value indicating a potential 79% upside.
Operating cash flow per share of Tandem Diabetes Care, Inc. – HAN:TD5A
The article focuses on the operating cash flow per share of Tandem Diabetes Care, Inc., traded on the Hannover Stock Exchange under the symbol TD5A. It appears to be a stub or a placeholder page from TradingView, indicating where financial data for the company would typically be displayed. The content highlights the company's stock information and general financial overview sections available on the platform.
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries
Tandem Diabetes Care has announced the expansion of its t:slim X2 insulin pump with Control-IQ technology to 12 new countries. This move signifies a major step in making advanced automated insulin delivery systems more widely available globally, offering improved diabetes management for a broader patient population. The expansion reflects the company's commitment to innovation and international growth in the diabetes care market.
Tandem Diabetes Care, Inc. (0M0F.L) Stock Price, News, Quote & History
This page provides stock information for Tandem Diabetes Care, Inc. (0M0F.L) on Yahoo Finance. It displays the current stock price, recent changes, and offers links to various data points like news, historical data, financial performance, and community discussions. The stock closed at 16.14 USD, up 3.03%, as of September 29th.
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries
Tandem Diabetes Care (TNDM) has expanded the availability of its Mobi automated insulin delivery system to 12 new countries. The article indicates that full access to this news requires a premium subscription.
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Diabetes Care announced the international launch of its Tandem Mobi automated insulin delivery system in twelve countries, including Belgium, Germany, and the UK. This system, powered by Control-IQ+ technology, is the world's smallest durable insulin pump and integrates with the Dexcom G7 continuous glucose monitoring system. The company plans further expansion of availability in additional countries.
A Look at Tandem Diabetes Care Inc (TNDM) After 3.3% Gain -- GF Value $24.10 vs Price $15.72
Tandem Diabetes Care Inc (TNDM) recently saw its shares rise by 3.3% to $15.72. According to GuruFocus's GF Value™, the stock is significantly undervalued at 34.8% below its estimated fair value of $24.10, earning it a "Possible Value Trap" label due to its unprofitability and negative cash flow. The company has an above-average GF Score™ of 68/100, bolstered by strong momentum, but faces challenges in financial strength and profitability, with no insider buying activity reported in the past year.
Tandem Insulin Pump Lawsuit Alleges Delivery Failure Led to 15-Year-Old Girl’s Death
A wrongful death lawsuit has been filed against Tandem Diabetes Care Inc., Unomedical A/S, Unomedical Devices S.A. de C.V., and Convatec Inc., alleging that a defective Tandem t:slim X2 insulin pump and infusion set led to the death of 15-year-old Celeste Seal. The lawsuit claims that the cannula became kinked, preventing insulin delivery and causing severe metabolic complications and anoxic brain injury due to a lack of effective audible warnings. Celeste's parents contend that the pump's safety systems should have detected the insulin under-delivery and alerted the family, allowing for timely intervention.
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating
Truist has lowered its price target for Tandem Diabetes Care (TNDM) from $31 to $28 but maintained a "Buy" rating on the stock. This adjustment comes amidst various analyst actions, including price target changes and rating adjustments from other firms like RBC, Deutsche Bank, and UBS. The article also provides recent news and financial updates related to Tandem Diabetes Care.
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating
Truist has lowered its price target for Tandem Diabetes Care (TNDM) to $28 from $31, while maintaining a Buy rating on the stock. Tandem Diabetes Care currently holds an average rating of "overweight" with a mean price target of $29. The full MT Newswires article requires a premium subscription to access.
Officer at Tandem Diabetes Care (NASDAQ: TNDM) plans 360-share stock sale
An officer at Tandem Diabetes Care (TNDM), Mark Novara, plans to sell up to 360 shares of common stock, valued at an estimated $6,310.80, through Morgan Stanley Smith Barney LLC on Nasdaq. This proposed sale is related to restricted stock units dated September 15, 2026, and follows a previous 10b5-1 sale of 131 shares by Novara on August 18, 2026. The SEC filing provides details on the transaction and relevant regulatory terms like Rule 144 and 10b5-1 plans.
(TNDM) Movement Within Algorithmic Entry Frameworks
This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM) using algorithmic entry frameworks, highlighting divergent sentiment across different time horizons. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tandem Diabetes Care (TNDM) has experienced a 26.5% decline in its stock price over the past four weeks, but indicators suggest a potential trend reversal. The stock is technically in oversold territory according to the Relative Strength Index (RSI), and Wall Street analysts have raised earnings estimates for the company, further supporting the possibility of a rebound. TNDM also holds a Zacks Rank #2 (Buy), indicating strong potential for near-term turnaround.
William Blair initiates Tandem Diabetes stock with outperform rating
William Blair initiated coverage on Tandem Diabetes Care (NASDAQ:TNDM) with an outperform rating, citing the company's strong pipeline, including the upcoming Mobi tubeless pump, and shifting selling model. Despite being unprofitable, the stock is considered undervalued by InvestingPro, and the company recently reported improved Q2 2026 financials with increased sales and gross margins. Oppenheimer also reiterated an Outperform rating, highlighting growth from pharmacy-channel sales and new products.
TNDM Initiated Coverage On by William Blair -- Rating Set to Outperform
William Blair initiated coverage on Tandem Diabetes Care (TNDM) with an 'Outperform' rating. The stock is considered 7.1% undervalued according to GF Value™, despite the company currently being unprofitable. Tandem Diabetes Care's GF Score™ is 71/100, reflecting strong growth and momentum but weaknesses in financial strength and profitability, warranting careful consideration from investors.
How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors
Tandem Diabetes Care (TNDM) reported a Q2 2026 net loss of US$21.17 million despite sales of US$254.56 million, while reaffirming full-year sales guidance of US$1.07 billion to US$1.09 billion. The company is pivoting towards pharmacy-based pump distribution and new insulin delivery technologies, a strategic shift that could impact its revenue generation and long-term earnings profile. Investors are advised to consider the potential of this pharmacy expansion against competitive risks and shifting reimbursement terms.
Tandem Diabetes (TNDM) CFO vests RSUs as shares withheld for tax
Tandem Diabetes Care Inc. (TNDM) CFO Leigh Vosseller vested two blocks of Restricted Stock Units (RSUs) on August 15, 2026, acquiring 1,496 and 2,624 shares of common stock. To satisfy tax withholding obligations, the company withheld 537 and 942 shares at $22.72 per share, with no shares being sold. Following these transactions, Vosseller indirectly holds 25,580 shares in the Leigh A. Vosseller Trust.
Tandem Diabetes (NASDAQ: TNDM) exec nets 475 shares after RSU vesting
Tandem Diabetes Care Inc.'s EVP & Chief Operating Officer, Jean-Claude Kyrillos, reported the vesting of 1,010 restricted stock units (RSUs) on August 15, 2026. Of these, 535 shares were withheld by the company at $22.72 each to cover tax obligations, resulting in a net issuance of 475 shares. Following this transaction, Kyrillos now holds 7,067 RSUs that are set to vest in future quarterly installments.
Tandem Diabetes (NASDAQ: TNDM) CLO RSUs vest, with shares withheld for taxes
Tandem Diabetes Care Inc.'s EVP & Chief Legal Officer, Shannon Marie Hansen, had 3,014 Restricted Stock Units (RSUs) vest on August 15, 2026. Of these, 1,535 shares were withheld at $22.72 per share to cover tax obligations, with no open-market sales. The filing also reports an indirect holding of 1,935 common shares in the Shannon M. Hansen Trust.
Tandem Diabetes Care CFO Leigh Vosseller Reports RSU Vesting Transactions on August 15, 2026
Leigh Vosseller, CFO of Tandem Diabetes Care (NASDAQ:TNDM), reported RSU vesting transactions on August 15, 2026. These included the vesting of 1,496 shares from a May 2024 grant and 2,624 shares from a May 2025 grant, with shares withheld for tax obligations at $22.72 per share. Following these transactions, Vosseller directly owns 52,040 shares and indirectly holds 25,580 shares.
Tandem Diabetes (NASDAQ: TNDM) EVP issued 2,827 shares, 809 withheld
Tandem Diabetes Care Inc.'s EVP & Chief Admin. Officer, Susan Morrison, acquired 2,827 shares of common stock through the vesting of restricted stock units (RSUs) on August 15, 2026. The company withheld 809 shares at $22.72 each to cover tax obligations, resulting in a net acquisition of 2,018 shares. This transaction reflects equity compensation vesting and not open-market trading.
Is Tandem Diabetes Care (TNDM) Undervalued Following Q2 Earnings And Reaffirmed Guidance?
Tandem Diabetes Care (TNDM) is under fresh scrutiny after its Q2 2026 earnings, which showed increased sales, a narrower net loss, and reaffirmed full-year revenue guidance near $1 billion. Despite meeting Wall Street expectations, the stock sold off due to investor caution regarding U.S. pump shipments and a business model transition. While the stock has seen recent momentum with a 30% gain over the last month and 105% over the past year, its long-term performance has been mixed, leading to questions about whether its improving story is fully reflected in its current valuation, which Simply Wall St estimates to be undervalued by 23.8%.
Is Tandem Diabetes Care (TNDM) Undervalued Following Q2 Earnings And Reaffirmed Guidance?
Tandem Diabetes Care (TNDM) reported higher Q2 2026 sales and a narrowed net loss, reaffirming full-year revenue guidance. Despite meeting Wall Street expectations, the stock saw a post-earnings sell-off due to investor caution regarding U.S. pump shipments and a business model transition. However, the company's stock has shown strong recent performance, and a popular valuation narrative suggests it is currently undervalued with a fair value near $29.20.
Renaissance Technologies LLC Purchases New Position in Tandem Diabetes Care, Inc. $TNDM
Renaissance Technologies LLC has acquired a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), purchasing 58,227 shares valued at approximately $1.12 million. Other institutional investors like Vanguard Group and Jennison Associates also increased their holdings. Tandem Diabetes Care reported mixed quarterly results with revenue up 5.8% year-over-year but still posted a loss per share, narrowly beating analyst estimates.
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes Care (TNDM) reported a narrower-than-expected loss of 31 cents per share in Q2 2026, beating the Zacks Consensus Estimate. However, worldwide revenues of $254.6 million missed expectations. Despite the revenue miss, the stock gained 19.1% following the announcement, driven by increased pump shipments, favorable pricing, and improved product costs.
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes Care (TNDM) reported a Q2 2026 loss of 31 cents per share, which was narrower than expected, though worldwide revenues of $254.6 million missed consensus estimates. Despite the revenue miss, the company's shares rose 19.1% after the announcement, driven by increased pump shipments, favorable pharmacy-channel pricing, and improved product costs, leading to a significant expansion in gross margin. TNDM reaffirmed its 2026 sales guidance and maintains a solid cash position.
Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Analyzing 25% Potential Upside with No Sell Ratings
Tandem Diabetes Care, Inc. (TNDM) presents a high-risk, high-reward investment opportunity in the medical devices industry, with analysts projecting a 25% potential upside and no sell ratings. Despite current financial challenges like negative EPS and free cash flow, the company is bullishly positioned above moving averages, thanks to its innovative diabetes management solutions and strong R&D investments. Tandem's strategic collaborations and focus on advanced insulin delivery systems underscore its long-term growth potential in the competitive healthcare market.
Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Reaffirming 2026 Outlook And Highlighting Mobi Momentum
Tandem Diabetes Care (TNDM) saw its stock rise 14.8% after reaffirming its full-year 2026 sales outlook of US$1.07–1.09 billion and highlighting early success with its Pay-As-You-Go pharmacy model and growing adoption of its Mobi platform. The company reported second-quarter sales of US$254.56 million and a reduced net loss, while also making progress towards FDA clearance for new tubeless capabilities. This positive news helps frame how these catalysts might impact revenue this year, though competitive pressures remain a key risk.
Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Record Q2 Sales And PayGo Momentum
Tandem Diabetes Care (TNDM) saw its stock rise 14.8% after reporting record Q2 2026 worldwide sales of US$254.56 million, a higher gross margin, and a reduced net loss, while reaffirming its full-year sales guidance of US$1.07 billion. The company's new PayGo pharmacy model, which accounts for about 10% of U.S. shipments and 45% formulary coverage, is gaining momentum, signaling a shift towards more recurring revenue streams. This positive performance reinforces the company's investment narrative, although competitive risks persist.
Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results
Tandem Diabetes Care (TNDM) reported strong Q2 2026 results with record worldwide sales and reaffirmed full-year guidance, leading to a significant rally in its share price. Despite the recent gains, Simply Wall St. suggests that TNDM is still undervalued by 23.4%, with a fair value estimated at $29.20. The positive outlook is attributed to expected pharmacy channel expansion, increased pump adoption, and improved margins, though the company faces competition and reimbursement uncertainties.
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care reported strong Q2 results with record sales, pump shipments, and gross margin, driven by its transition to pharmacy-channel reimbursement and new insulin-delivery technologies. The company saw a 6% year-over-year increase in worldwide sales to $255 million and shipped approximately 33,000 insulin pumps globally. Despite near-term revenue headwinds from the pharmacy channel transition, Tandem reaffirmed its 2026 outlook and highlighted pipeline developments for new pump features and infusion technologies.
Tandem Diabetes Care (TNDM) Stock Jumps As Margin Recovery Steals The Spotlight
Tandem Diabetes Care's stock surged 19% after its Q2 earnings report, despite a net loss, due to a significant recovery in gross margin to 57%. Revenue grew 6%, and the net loss narrowed by 60%, with strong performance in international pump shipments and an increasing presence in Pharmacy PayGo. While the margin improvement is positive, concerns remain regarding continued losses and capital allocation risks.
Tandem Diabetes Care, Inc. Stock 12‑Month Price Target Raised to $29.5, Implies 57% Upside
Analysts have raised the average 12-month price target for Tandem Diabetes Care, Inc. (TNDM) stock to $29.5, up from $29.19. This new target suggests a potential upside of approximately 57% from its August 6th closing price. The consensus rating among 22 analysts remains a "Buy," with 12 recommending a Buy and 10 a Hold.
Tandem Diabetes Care Inc (TNDM) News, Articles, Events & Latest Updates
Tandem Diabetes Care Inc (TNDM) reported Q2 2026 financial results, including a loss and lagging revenue estimates, despite some key metrics showing positive movement. The company announced upcoming conference presentations, product compatibility expansions, and plans to release Q2 results in August 2026. This news comes as next-generation diabetes therapies are reshaping healthcare, presenting multi-billion-dollar revenue opportunities in the market.
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care reported strong second-quarter results with record sales, pump shipments, and gross margin, driven by progress in pharmacy-channel reimbursement and new insulin-delivery technologies. The company saw increased U.S. and international sales, though pharmacy-channel transition created a near-term revenue headwind. Tandem reaffirmed its 2026 financial outlook and provided updates on pipeline developments, including a tubeless feature for the Mobi pump and a new infusion technology.
Tandem Diabetes Care, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNDM)
Tandem Diabetes Care, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$0.31, which beat estimates by $0.01. The company's revenue for the quarter was $254.56M, representing a 5.77% year-over-year increase, though it missed revenue expectations by $510.18K. The slide deck accompanies their earnings call from August 7, 2026.
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
Tandem Diabetes Care, Inc. reported strong financial results for Q2 2026, with worldwide sales increasing 6% to $254.6 million and gross margin up 460 basis points to 57%. The company also highlighted strategic achievements, including FDA submissions for Tandem Mobi, expanded global technology solutions, and reaffirmed its full-year 2026 financial guidance for sales between $1.065 billion and $1.085 billion.
Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - What's Next?
Tandem Diabetes Care (NASDAQ:TNDM) shares gapped down but later rose by 13.8%. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $28.77, though Mizuho lowered its target to $20. The company reported an adjusted loss of $0.31 per share, beating estimates, with revenue up 5.8% year-over-year, but remains unprofitable.
Tandem Diabetes Care (NASDAQ: TNDM) lifts Q2 sales to $254.6M, trims loss
Tandem Diabetes Care reported strong second-quarter 2026 results, with worldwide sales increasing by 6% to $254.6 million and a significant improvement in gross margin to 57%. The company also narrowed its GAAP net loss to $21.2 million and achieved positive Adjusted EBITDA of $6.4 million. Tandem reaffirmed its full-year 2026 sales guidance and highlighted strategic milestones including new FDA clearances and the international rollout of Tandem Mobi.
TANDEM DIABETES CARE INC 2026: Revenue $254.56M, EPS ($0.31) — 10-Q Summary
Tandem Diabetes Care Inc. (TNDM) reported its 2026 quarterly results, showing revenue of $254.56 million, an increase from $240.68 million in the previous year. The company significantly reduced its net loss to ($21.17 million) from ($52.4 million) year-over-year, with diluted loss per share narrowing to ($0.31) from ($0.78). Revenue growth was attributed to higher pump volumes and improved pricing, despite supply constraints from an infusion set supplier.
Tandem Diabetes Q2 2026 slides: PayGo model drives margin expansion
Tandem Diabetes Care (NASDAQ:TNDM) reported record Q2 2026 sales of $255 million, despite a slight miss on revenue forecasts, driven by a strategic transition to a "PayGo" pharmacy-based reimbursement model. This new model is expected to more than double lifetime revenue per patient and improve gross margins. The company reaffirmed its full-year 2026 guidance, projecting sales of $1.065 billion to $1.085 billion, and anticipates significant long-term profitability improvements as the transition progresses.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) reported a Q2 loss of $0.31 per share, exceeding the Zacks Consensus Estimate of a $0.34 loss, marking an 8.82% surprise. Despite this, the company's Q2 revenues of $254.56 million missed the consensus estimate by 0.1%, leading to an unfavorable Zacks Rank of #4 (Sell) for the stock. Analysts anticipate a loss of $0.22 per share on $268.05 million in revenues for the coming quarter and a full-year loss of $0.72 per share on $1.08 billion in revenues.
Voya Financial (TNDM holder) discloses 149,088 Tandem Diabetes Care shares in 13G/A
Voya Financial, Inc. has filed an amended Schedule 13G/A, disclosing its beneficial ownership of 149,088 shares of Tandem Diabetes Care, Inc. common stock, which represents a 0.2% stake in the company. Voya Financial asserts sole voting and dispositive power over these shares. The filing indicates this ownership is less than 5% of the class and is held by Voya as the ultimate parent company of its wholly-owned subsidiaries.
Tandem Diabetes Care (TNDM) Rebounds On Growth Hopes, Is The Stock Still Undervalued?
Tandem Diabetes Care (TNDM) has seen a recent rebound in its stock price, trading around $20.20, with a market value near $1.38 billion, despite longer-term declines. Analysts suggest the stock is undervalued with a fair value of $29.20, driven by expectations of future earnings power and margin expansion from pharmacy channel growth. However, the company faces risks from competition and potential complexity from expansion.
Tandem Diabetes Care (TNDM) Rebounds On Growth Hopes, Is The Stock Still Undervalued?
Tandem Diabetes Care (TNDM) has seen a recent rebound in its stock price, with a 31% gain over 30 days, despite longer-term declines. The company is considered 30.8% undervalued with a fair value of $29.20 compared to its current $20.20, driven by expectations of future earnings growth and margin expansion through pharmacy channel expansion. However, risks like competition and operational complexities could impact these projections.
